Eli Lilly’s latest TV ad, unveiled during the Grammys on Sunday night, highlights the importance of early diagnosis for ...

The biotech has named Jamie Coleman its chief commercial officer, per a Monday announcement, putting her in charge of the ...

Eli Lilly investors and analysts said they want to hear details from the company on how exactly it plans to grow U.S. sales ...

Eli Lilly's Ozempic-rivaling weight-loss pill orforglipron could be available in early 2026. Its retatrutide may be as ...

The U.S. Food and Drug Administration ordered a hold on a study of an early-stage obesity drug being developed by Amgen, another potential setback in the company’s efforts to join the booming weight ...

(Reuters) -Eli Lilly's obesity drug Zepbound can now be covered ... for a secondary use by the Food and Drug Administration. Commercial insurers and employers were previously hesitant to cover ...

Lilly is currently rising high in the obesity category with blockbuster ... include up to $1 billion in preclinical, clinical, and commercial milestone payments, as well as royalties on product ...

Since commercial insulin ... Novo Nordisk and Eli Lilly are both excellent companies. The former has world leadership in products against obesity and diabetes, the latter in recent years has ...

That won't happen now, but Lilly says it will start a rolling application for the drug in obesity this year that ... teams can leverage the At the Veeva Commercial Summit in Madrid at the end ...

Commercial insurers and employers ... to reduce the risk of heart attacks and strokes. Lilly and Novo are testing their blockbuster obesity drugs for a range of conditions as they race to ...